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The per capita number of outpatient visits in which an antipsychotic drug was supplied or 
prescribed increased approximately 660% among children and 380% among adolescents 
between the mid-1990s and the mid-2000s in the United States,1 prompting concerns about 
possible inappropriate prescribing. The most recent revisions to the DSM-5 were intended in 
part to decrease inappropriate child and adolescent antipsychotic drug use,2 and the 
American Psychiatric Association has warned against using antipsychotics as first-line 
therapy in children and adolescents for conditions other than psychotic disorders.3 To 
quantify acute harms from child and adolescent antipsychotic drug use, we estimated the 
numbers and rates of US emergency department (ED) visits and hospitalizations for adverse 
drug events (ADEs) from therapeutic use of antipsychotics and comparator psychotropic 
medications among children 10 years or younger and adolescents 11 to 18 years.
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Methods
We used the National Electronic Injury Surveillance System–Cooperative Adverse Drug 
Event Surveillance (NEISS-CADES) system to estimate child and adolescent US ADE ED 
visits from antipsychotics, antidepressants, and stimulants available only by prescription 
(2009-2011) and estimated child and adolescent outpatient prescription visits using the 
National Ambulatory Medical Care and National Hospital Ambulatory Medical Care 
Surveys (2009-2010).4-6 We excluded ADE ED visits resulting from therapeutic failures, 
nonadherence, drug withdrawal, and nontherapeutically intentioned use (intentional self-
harm, drug abuse, or unsupervised ingestions) or involving ADEs that led to a patient's death 
in or before arrival at the ED. We also calculated the annual number of ADE ED visits per 
10 000 outpatient visits at which each medication was prescribed. We classified medications 
as antipsychotics, antidepressants, or stimulants; categorized adverse effects; and calculated 
95% CIs as described by Hampton et al.4
The human participant oversight bodies of the Centers for Disease Control and Prevention 
and Food and Drug Administration determined the methods and analyses in this study to be 
public health surveillance activities and did not require institutional review board approval 
or patient consent.
Results
From 2009 through 2011, there were an estimated 1350 antipsychotic ADE ED visits (95% 
CI, 821-1879) involving children 10 years and younger and 2674 visits (95% CI, 
1779-3569) involving adolescents 11 to 18 years old annually in the United States (Table 1). 
Patients were admitted, held for observation, or transferred to another acute care facility 
after 18.6% of child and adolescent antipsychotic ADE ED visits (95% CI, 12.3%-24.9%), a 
hospitalization rate higher than the 7.3% rate (95% CI, 4.0%-10.5%) for nonantipsychotic 
ADE ED visits. Atypical antipsychotics were implicated in 97.6% of child antipsychotic 
ADE ED visits (95% CI, 94.0%-100.0%) and 83.4% of adolescent visits (95% CI, 
77.2%-89.7%). Among children, antipsychotics were implicated in ADE ED visits at a 3.9-
fold higher rate than stimulants (17.6 vs 4.5 ADE ED visits per 10 000 out-patient 
prescription visits) (Table 2). Among adolescents, antipsychotics were implicated in ADE 
ED visits at a 3.8-fold higher rate than stimulants (14.6 vs 3.8 ADE ED visits per 10 000 
outpatient prescription visits) and a 2.7-fold higher rate than antidepressants (14.6 vs 5.5 
ADE ED visits per 10 000 outpatient prescription visits). Movement disorders, including 
dystonia, extrapyramidal disorders, and muscle spasticity, were the most common 
antipsychotic drug adverse effects, occurring in 47.7% of child and adolescent antipsychotic 
ADE ED visits (95% CI, 37.8%-57.6%).
Discussion
Adverse events from therapeutically intentioned use of antipsychotics cause thousands of 
child and adolescent ED visits annually in the United States and significantly more ED visits 
relative to their outpatient use than either stimulants or antidepressants. These national 
estimates are probably conservative because the NEISS-CADES may be biased toward the 
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detection of drug adverse effects that are acute, known, testable in an ED, or readily 
distinguished from problems caused by patients’ comorbidities.4 Chronic problems from 
medication use, such as metabolic disorders associated with antipsychotics,3 are unlikely to 
be identified by the NEISS-CADES. In addition, the NEISS-CADES does not collect 
information on the specific indication for each medication implicated in an ADE or on 
whether a medication was used on label or off label. National Ambulatory Medical Care 
Survey and National Hospital Ambulatory Medical Care Survey data are commonly used to 
estimate outpatient medication use1,4; however, they do not provide direct estimates of 
person-year exposure to medications and may overestimate or underestimate the use of 
psychiatric medications.
The higher rates of antipsychotic ADE ED visits should remind clinicians of antipsychotics’ 
risks and of the importance of heeding the American Psychiatric Association's warning that 
antipsychotics should be used cautiously.3 Nationally representative public health 
surveillance data may be useful in assessing the impact of efforts to reduce inappropriate 
antipsychotic drug use on ADEs.
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Table 1
Numbers of Cases and National Estimates of Annual Pediatric ED Visits for Antipsychotic Drug Adverse 
Events by Patient and Case Characteristics in the United States, 2009-2011
ED Visits for Adverse Eventsa
Estimated Annual Visits
Characteristic No. of Cases No. of Visits % (95% CI)
Age, y
    0-10 86 1350 33.5 (25.1-42.0)
    11-18 178 2674 66.5 (58.0-74.9)
Sex
    Male 173 2592 64.4 (58.1-70.8)
    Female 91 1432 35.6 (29.2-41.9)
Mechanism of adverse event
    Adverse reaction 188 2807 69.8 (59.6-79.9)
    Unintentional overdose or supratherapeutic effects 50 731 18.2 (11.3-25.0)
    Allergic reaction 25 447 11.1 (5.0-17.2)
    Secondary effect 1 SUE SUE
Disposition
    Admitted, observed, or transferred 60 748 18.6 (12.3-24.9)
    Treated and released or left against medical advice 204 3276 81.4 (75.1-87.7)
No.of implicated medications
    1 192 3036 75.4 (69.0-81.9)
    2 72 988 24.6 (18.1-31.0)
No. of concurrent medications
    None listed 82 1260 31.3 (20.6-42.0)
    1-2 108 1800 44.7 (32.4-57.1)
    ≥3 74 SUE 24.0 (11.5-36.4)
Total 264 4024
Abbreviations: ED, emergency department; SUE, statistically unstable estimate.
a
The number of cases and national estimates of ED visits from the National Electronic Injury Surveillance System–Cooperative Adverse Drug 
Event Surveillance system. Emergency department visits for adverse drug events include visits in which the specified prescription medication was 
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either the only medication implicated or was implicated along with other medications. This excludes ED visits resulting from intentional self-harm, 
drug abuse, therapeutic failures, noncompliance, drug withdrawal, or unsupervised ingestions.
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Table 2
Numbers of Cases and National Estimates of Annual Pediatric ED Visits for Antipsychotic, Antidepressant, 
and Stimulant Medication Adverse Events by Patient Age and Medication Category in the United States, 
2009-2011
Medication
ED Visits for Adverse Eventsa Estimated Annual 
Prescription Visits, No. 
(1000s)b
Estimated Annual ED Visits/10 000 
Outpatient Prescription Visits, No. 
(95% CI)No. of Cases Estimated Annual No. 
of Visits
0-10 y
Antipsychotics 86 1350 1534 17.6 (13.1-22.1)
    Atypical antipsychotics 83 1318 1504 17.5 (12.9-22.2)
Stimulantsc 134 1841 8178 4.5 (3.4-5.6)
Antidepressants 24 SUE 1498 SUE
11-18 y
Antipsychotics 178 2674 3657 14.6 (11.2-18.0)
    Atypical antipsychotics 152 2231 3603 12.4 (9.4-15.4)
Antidepressantsd 136 2281 8250 5.5 (4.3-6.7)
Stimulantsc 128 2057 10884 3.8 (2.9-4.7)
Abbreviations: ED, emergency department; SUE, statistically unstable estimate.
aNumber of cases and national estimates of ED visits from the National Electronic Injury Surveillance System–Cooperative Adverse Drug Event 
Surveillance system. Emergency department visits for adverse drug events include visits in which the specified prescription medication was either 
the only medication implicated or was implicated along with other medications. This excludes ED visits resulting from intentional self-harm, drug 
abuse, therapeutic failures, noncompliance, drug withdrawal, or unsupervised ingestions.
b
Estimated annual numbers of outpatient prescription visits for each medication are from the National Ambulatory Medical Care Survey and 
National Hospital Ambulatory Medical Care Survey for 2009 and 2010 and include outpatient prescription visits in which multiple psychiatric 
medications were prescribed at a single visit.
cAmphetamines were implicated in 93.8% (95% CI, 88.7%-98.9%) and 88.0% (95% CI, 81.4%-94.5%) of stimulant adverse drug event ED visits 
involving children 0 to 10 years old and adolescents 11 to 18 years old, respectively.
dSelective serotonin reuptake inhibitors were implicated in 59.7% (95% CI, 45.4%-74.0%) of antidepressant adverse drug event ED visits 
involving adolescents 11 to 18 years old.
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